Publications

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial

Researchers conducted this randomised, double-blind, placebo-controlled, phase 2 trial to test the safety and effectiveness of adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs a placebo in patients with stage IV melanoma with no evidence of disease.

Read More

Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response

Given that objective responses in 30% to 50% of patients suffering from metastatic melanoma is mediated by adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), as per multiple, small phase 2 trials, so, researchers assessed long-term clinical outcomes, intent-to-treat analysis, predictors of response as well as toxicity profile in a large patient cohort.

Read More
MRV News
Melanoma News
Archive
Menu